Development Pipeline

Reimagining therapeutics

At Biora, we are creating innovative smart-pill technologies to improve patients’ lives. Our ingestible drug-device combinations could enable new treatment approaches in the delivery of oral biotherapeutics. We are focused on two primary areas:

Targeted Therapeutics Pipeline

Our Targeted Therapeutics program uses an ingestible smart capsule designed for targeted delivery of therapeutics in the gastrointestinal tract to improve the treatment of IBD. Delivering therapeutics directly to the site of disease could enable safer and more effective drug therapies.

Learn More
Program Indication Design / Feasibility Preclinical Clinical

DDS
Device

 IBD
Clinical

PGN-600
Tofacitinib + Device

 Ulcerative Colitis
Preclinical

PGN-001
Adalimumab + Device

 Ulcerative Colitis
Preclinical

Systemic Therapeutics Pipeline

Our Systemic Therapeutics program uses an ingestible capsule designed for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. With more frequent administration, oral delivery has the potential to improve drug efficacy and safety as compared to current injection regimens.

Learn More
Program Indication Design / Feasibility Preclinical Clinical

OBDS
Device

 –
Preclinical

PGN-OB1
Adalimumab variant + Device

 Autoimmune
Preclinical

PGN-OB2
GLP-1 agonist + Device

 Diabetes
Preclinical

Ionis Collaboration
Antisense therapy + Device

 Undisclosed
Design/Feasibility

Large Pharma 1 Collaboration
Undisclosed drug + Device

 Undisclosed
Design/Feasibility

Large Pharma 2 Collaboration
Undisclosed drug + Device

 Undisclosed
Design/Feasibility